Literature DB >> 2397611

Frequencies of interleukin-5 mRNA-producing cells in healthy individuals and in immunoglobulin-deficient patients, measured by in situ hybridization.

C I Smith1, G Möller, E Severinson, L Hammarström.   

Abstract

Interleukin-5 (IL-5) has previously been demonstrated to enhance immunoglobulin synthesis, especially IgA. Thus, it could be hypothesized that a defect production of IL-5 may cause immunoglobulin deficiency. We have analysed the frequency of IL-5 mRNA-producing cells in healthy adults and in patients with common variable immunodeficiency or selective IgA deficiency. Unstimulated lymphocytes were rarely found to synthesize IL-5 as measured by in situ hybridization. However, pokeweed mitogen and several other activating ligands induced the synthesis of IL-5 mRNA in peripheral blood and spleen lymphocyte cultures. After pokeweed mitogen activation, the number of IL-5 mRNA-producing cells most often peaked on day 3 with a maximal frequency of around 1-2% of mononuclear cells. In a kinetic study we were unable to detect any peak frequency differences between healthy controls (mean 0.44%) and 20 patients (mean 0.58%). Thus, although IL-5 has been reported to be an important regulator of IgA synthesis, a defect production does not seem to be the underlying mechanism in human immunoglobulin deficiency.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2397611      PMCID: PMC1534998          DOI: 10.1111/j.1365-2249.1990.tb05349.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  IgA2 allotypes determined by restriction fragment length polymorphism in IgA deficiency. Re-expression of the silent A2m(2) allotype in the children of IgA-deficient patients.

Authors:  L Hammarström; G G de Lange; C I Smith
Journal:  J Immunogenet       Date:  1987 Aug-Oct

2.  Immunoglobulin heavy-chain switching may be directed by prior induction of transcripts from constant-region genes.

Authors:  J Stavnezer; G Radcliffe; Y C Lin; J Nietupski; L Berggren; R Sitia; E Severinson
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

3.  Simultaneous production of IL-2, IL-4, and IFN-gamma by activated human CD4+ and CD8+ T cell clones.

Authors:  X Paliard; R de Waal Malefijt; H Yssel; D Blanchard; I Chrétien; J Abrams; J de Vries; H Spits
Journal:  J Immunol       Date:  1988-08-01       Impact factor: 5.422

4.  Recombinant murine IL-5 induces high rate IgA synthesis in cycling IgA-positive Peyer's patch B cells.

Authors:  K W Beagley; J H Eldridge; H Kiyono; M P Everson; W J Koopman; T Honjo; J R McGhee
Journal:  J Immunol       Date:  1988-09-15       Impact factor: 5.422

5.  Interleukin 5 enhances interleukin 4-induced IgE production by normal human B cells. The role of soluble CD23 antigen.

Authors:  J Pène; F Rousset; F Brière; I Chrétien; J Wideman; J Y Bonnefoy; J E De Vries
Journal:  Eur J Immunol       Date:  1988-06       Impact factor: 5.532

Review 6.  T cell-replacing factor (TRF)/interleukin 5 (IL-5): molecular and functional properties.

Authors:  K Takatsu; A Tominaga; N Harada; S Mita; M Matsumoto; T Takahashi; Y Kikuchi; N Yamaguchi
Journal:  Immunol Rev       Date:  1988-02       Impact factor: 12.988

Review 7.  Molecular and cellular biology of eosinophil differentiation factor (interleukin-5) and its effects on human and mouse B cells.

Authors:  C J Sanderson; H D Campbell; I G Young
Journal:  Immunol Rev       Date:  1988-02       Impact factor: 12.988

8.  Restricted production of interleukin 4 by activated human T cells.

Authors:  D B Lewis; K S Prickett; A Larsen; K Grabstein; M Weaver; C B Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

9.  Characterization of T helper 1 and 2 cell subsets in normal mice. Helper T cells responsible for IL-4 and IL-5 production are present as precursors that require priming before they develop into lymphokine-secreting cells.

Authors:  S L Swain; D T McKenzie; A D Weinberg; W Hancock
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

10.  Receptors for T cell-replacing factor/interleukin 5. Specificity, quantitation, and its implication.

Authors:  S Mita; N Harada; S Naomi; Y Hitoshi; K Sakamoto; M Akagi; A Tominaga; K Takatsu
Journal:  J Exp Med       Date:  1988-09-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Therapeutic strategies in common variable immunodeficiency.

Authors:  W A Carrock Sewell; Matthew Buckland; Stephen R A Jolles
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Cytokine expression by high-density human lymphocytes.

Authors:  W A Sewell; M F Berger; L J Skipsey; M A Cooley; H S Warren
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

3.  Increased IL-6 gene expression and production in patients with common variable immunodeficiency.

Authors:  F Pandolfi; R Paganelli; A Oliva; I Quinti; V Polidori; E Fanales-Belasio; E Guerra; F Aiuti
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

4.  Primary antibody deficiency in Arabs: first report from eastern Saudi Arabia.

Authors:  R A al-Attas; A H Rahi
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

5.  Subclass composition and J-chain expression of the 'compensatory' gastrointestinal IgG cell population in selective IgA deficiency.

Authors:  D E Nilssen; P Brandtzaeg; S S Frøland; O Fausa
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

6.  Evidence for an abnormal profile of interleukin-4 (IL-4), IL-5, and gamma-interferon (gamma-IFN) in peripheral blood T cells from patients with allergic eosinophilic gastroenteritis.

Authors:  J S Jaffe; S P James; G E Mullins; L Braun-Elwert; I Lubensky; D D Metcalfe
Journal:  J Clin Immunol       Date:  1994-09       Impact factor: 8.317

Review 7.  Cytokines in common variable immunodeficiency as signs of immune dysregulation and potential therapeutic targets - a review of the current knowledge.

Authors:  Farnaz Najmi Varzaneh; Bärbel Keller; Susanne Unger; Asghar Aghamohammadi; Klaus Warnatz; Nima Rezaei
Journal:  J Clin Immunol       Date:  2014-05-15       Impact factor: 8.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.